Israel - Arabisch - Ministry of Health

teva pharmaceutical indust.ltd - alfacalcidol 1 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

Israel - Arabisch - Ministry of Health

sanofi - aventis israel ltd - hydrochlorothiazide 12.5 mg; ramipril 2.5 mg - tablets - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

Israel - Arabisch - Ministry of Health

salomon,levin & elstein ltd - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - film coated tablets - ampicillin, combinations - short-term treatment of bacterial infections at the following sites: upper/lower respiratory tract infections, genito-urinary tract infections, skin and soft tissue infections, bone and joint infections, dental infections and other infections.

Israel - Arabisch - Ministry of Health

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Israel - Arabisch - Ministry of Health

teva pharmaceutical indust.ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.